Mangrove Partners Mereo Biopharma Group PLC Transaction History
Mangrove Partners
- $642 Million
- Q4 2024
A detailed history of Mangrove Partners transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Mangrove Partners holds 8,636,485 shares of MREO stock, worth $25.3 Million. This represents 4.71% of its overall portfolio holdings.
Number of Shares
8,636,485
Previous 8,729,720
1.07%
Holding current value
$25.3 Million
Previous $35.9 Million
15.75%
% of portfolio
4.71%
Previous 4.66%
Shares
4 transactions
Others Institutions Holding MREO
# of Institutions
95Shares Held
114MCall Options Held
83.4KPut Options Held
424K-
Janus Henderson Group PLC London, X017.1MShares$50.2 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$44.9 Million0.89% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.6MShares$28.1 Million1.34% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.72MShares$25.5 Million0.06% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$19.7 Million0.58% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $366M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...